Karius

company

About

Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.

Details

Last Funding Type
Series B
Last Funding Money Raised
$165M
Industries
Biotechnology,Genetics,Health Care,Information Technology,Life Science
Founded date
Jan 1, 2014
Number Of Employee
101 - 250
Operating Status
Active
Legal Name
Karius, Inc.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
6
$254M
Karius has raised a total of $254M in funding over 2 rounds. Their latest funding was raised on Mar 7, 2022 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 7, 2022 Series B 2 Detail
Jan 20, 2021 Series B 1 Detail
Feb 24, 2020 Series B $165M 5 SoftBank Vision Fund Detail
Nov 30, 2018 Debt Financing $25M 1 Oxford Finance LLC Detail
Aug 5, 2017 Series A $59M 8 DCVC
Lightspeed Venture Partners
Detail

Employee Profiles

Number of Employee Profiles
13
Karius has 13 current employee profiles, including Board member Alexander Morgan
Board member
Board member
Executive
Advisor
Advisor